Bexarotene（Aladdin B125743） is a retinoid compound with high specificity for retinoid  X receptors (RXRs). It is approved as a chemotherapeutic for the treatment of cutaneous T-cell lymphoma and has also been investigated for its potential therapeutic role in Alzheimer’s disease.

The link between amyloid-β plaque accumulation and Alzheimer’s disease is well documented. Misfolded amyloid-β aggregates disrupt neuronal signaling by blocking the transmission of electrical and chemical messages within the brain. These peptides are derived from the cleavage of amyloid precursor protein (APP), a transmembrane glycoprotein. While the exact physiological function of amyloid-β remains unclear, its aggregation into plaques is a hallmark associated with the progression of Alzheimer’s disease.

Apolipoprotein E (ApoE) is a protein responsible for promoting the clearance of amyloid-β deposits. Its transcription is normally triggered by nuclear receptor activity, including RXR activation. Acting as an RXR agonist, bexarotene significantly increases soluble amyloid-β clearance within hours in animal models of Alzheimer’s disease. Within three days, plaque burden can be reduced by over 50%. Additionally, bexarotene has been shown to help reverse cognitive impairments and enhance neural circuit performance.

Healthy Neurons

Neurons surrounded by amyloid-β plaques

Ongoing studies continue to explore bexarotene’s effects in Alzheimer’s disease models and its potential in other research areas. Since RXR activation engages the body’s natural amyloid-β clearance pathways, bexarotene—along with other retinoic acid receptor (RAR) agonists such as 9-cis-Retinoic Acid (AladdinC134191) and 13-cis-Retinoic Acid (Aladdin I129856)—may hold increasing significance for investigations into neurodegenerative disorders.

References:

1. Tiraboschi P, Hansen LA, Thal LJ, et al. Neurology. 2004 Jun 8;62(11):1984-9.

2. Cramer P, Cirrito J, Wesson DW, et al. Science. 2012 Mar 23;335(6075):1503-6

Aladdin: https://www.aladdinsci.com/